Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewSiguazodan
Description: PDE3 inhibitor
Chemical Name: N-Cyano-N'-methyl-N''-[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]guanidine
Purity: ≥99% (HPLC)
Biological Activity
Phosphodiesterase inhibitor, selective for PDE3 (IC50 = 117 nM).
Technical Data
| M. Wt | 284.32 |
| Formula | C14H16N6O |
| Storage | Store at RT |
| Purity | ≥99% (HPLC) |
| CAS Number | 115344-47-3 |
| PubChem ID | 72124 |
| InChI Key | NUHPODZZKHQQET-UHFFFAOYSA-N |
| Smiles | CN\C(NC#N)=N/C1=CC=C(C=C1)C1=NNC(=O)CC1C |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| DMSO | 100 |
Preparing Stock Solutions
The following data is based on the product molecular weight 284.32. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 3.52 mL | 17.59 mL | 35.17 mL |
| 5 mM | 0.7 mL | 3.52 mL | 7.03 mL |
| 10 mM | 0.35 mL | 1.76 mL | 3.52 mL |
| 50 mM | 0.07 mL | 0.35 mL | 0.7 mL |
Molarity Calculator
Molarity Calculator
Calculate the mass, volume, or concentration required for a solution.
Reconstitution Calculator
Reconstitution Calculator
Dilution Calculator
Dilution Calculator
Calculate the dilution required to prepare a stock solution.
Product Datasheets
References
References are publications that support the biological activity of the product.
Freitag et al (1998) Phosphodiesterase inhibitors suppress α2-adrenoceptor-mediated 5-hydroxytryptamine release from trachea of newborn rabbits. Eur.J.Pharmacol. 354 67 PMID: 9726632
Tang et al (1994) Photoaffinity labelling of cyclic GMP-inhibited phosphodiesterase (PDE III) in human and rat platelets and rat tissues: effects of phosphodiesterase inhibitors. Eur.J.Pharmacol. 268 105 PMID: 7925608
Christensen and Torphy (1994) Isozyme-selective phosphodiesterase inhibitors as antiasthmatic agents. Annu.Rep.Med.Chem. 29 185
If you know of a relevant reference for Siguazodan, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Siguazodan, Siguazodan supplier, PDE3, inhibitors, inhibits, Phosphodiesterases, 1148, Tocris Bioscience
Citations for Siguazodan
Citations are publications that use Tocris products.
Currently there are no citations for Siguazodan. Do you know of a great paper that uses Siguazodan from Tocris? Please let us know.
Reviews for Siguazodan
There are currently no reviews for this product. Be the first to review Siguazodan and earn rewards!
Have you used Siguazodan?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Cardiovascular Research Product Guide
A collection of over 250 products for cardiovascular research, the guide includes research tools for the study of:
- Hypertension
- Thrombosis and Hemostasis
- Atherosclerosis
- Myocardial Infarction
- Ischemia/Reperfusion Injury
- Arrhythmias
- Heart Failure
Asthma Poster
Asthma is one of the most common chronic diseases in the world, affecting over 300 million people. This poster highlights key pathways and new therapies used to treat the condition, including those currently in clinical development.